Company Filing History:
Years Active: 2017
Title: Helen Hachemi: Pioneering Innovations in Antitumoral Therapeutics
Introduction
Helen Hachemi, an accomplished inventor based in Basel, Switzerland, is renowned for her groundbreaking work in the field of antitumoral therapies. With a strong focus on developing binding molecules that target specific antigens expressed on tumor cells, she has made significant contributions to cancer treatment methodologies.
Latest Patents
Helen holds a patent for her invention titled "Binding molecules with antitumoral activity." This innovative patent describes a binding molecule that specifically targets two different epitopes of an antigen found on tumor cells. The invention includes: (a) a first binding (poly)peptide derived from the Fyn SH3 polypeptide, which binds to a first epitope, and (b) a second binding (poly)peptide that interacts with a second epitope of the same antigen. Furthermore, the patent encompasses a nucleic acid molecule encoding the binding molecule, a vector containing the nucleic acid, and a host cell transformed with this vector. The invention is poised to play a significant role in pharmaceutical and diagnostic compositions, particularly for tumor treatment.
Career Highlights
Helen Hachemi's career at Covagen AG reflects her commitment to advancing oncological research. As an innovative scientist, she has contributed valuable insights and expertise to the company’s mission of developing targeted therapies that enhance patient outcomes. Her patent underscores her ability to blend scientific knowledge with practical applications in medicine.
Collaborations
Throughout her career, Helen has collaborated with notable coworkers, including Simon Brack and Frédéric Mourlane. These partnerships have enriched her research endeavors and have facilitated the sharing of ideas that drive forward the innovative solutions needed in the fight against cancer.
Conclusion
In summary, Helen Hachemi stands out as a trailblazer in the field of antitumoral innovation. Her dedication to creating binding molecules that effectively target tumor-specific antigens is a testament to her expertise and influence within the scientific community. Her patent not only highlights her ingenuity but also paves the way for future advancements in cancer treatment.